Treats uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae…. ANDA 210577, held by Amneal Pharms Co. Hydroxychloroquine Sulfate.
As of Nov 15, 2026, ANDA 210577 (Hydroxychloroquine Sulfate), held by Amneal Pharms Co, was first approved by FDA on May 15, 2018, with 4 approved supplements and 0 published complete response letters.
Hydroxychloroquine sulfate tablets are an antimalarial and antirheumatic indicated for the: Treatment of uncomplicated malaria due to Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium vivax in adult and pediatric patients. Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported in adult and pediatric patients. Treatment of rheumatoid arthritis in adults. Treatment of systemic lupus erythematosus in adults. Treatment of chronic discoid lupus erythematosus in adults. Limitations of Use: Hydroxychloroquine sulfate tablets are not recommended for the: Treatment of complicated malaria.
| Date | Submission | Status | Documents |
|---|---|---|---|
| May 15, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Hydroxychloroquine Sulfate200MG · tablet;oral | Hydroxychloroquine Sulfate | Rx |
| May 20, 2024 | Supplement 15Labeling · Standard review | Approved | None posted |
| May 20, 2024 | Supplement 16Labeling · Standard review | Approved | None posted |
| Dec 9, 2022 | Supplement 9Labeling · Standard review | Approved | None posted |
| Dec 9, 2022 | Supplement 12Labeling · Standard review | Approved | None posted |
| May 15, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters